SCHEMBL4174089

SCHEMBL4174089

CCCn1c(=O)c2c(nc(Cc3ccccc3)n2CCNCC)n(CCc2ccccc2NC(=O)C(CC(=O)O)NC(=O)CCCCN)c1=O

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 2/20 0.38
CHRNB4 P30926 2/20 0.38
CHRNA3 P32297 2/20 0.38
CHRNA4 P43681 2/20 0.38
TSHR P16473 2/20 0.38
ADORA2B P29275 3/20 0.37
ADORA2A P29274 1/20 0.37
ITGB3 P05106 1/20 0.34
ITGA2B P08514 1/20 0.34
CASP1 P29466 2/20 0.33
ADORA1 P30542 3/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
GHSR Q92847 1/20 0.33
THRB P10828 1/20 0.33
TP53 P04637 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4184656 0.99 CHRNB2 (0.38) CHRNB2CHRNB4CHRNA3CHRNA4TSHR
SCHEMBL4184661 0.93 CHRNB2 (0.36) CHRNB2CHRNB4CHRNA3CHRNA4TSHR
SCHEMBL5831724 0.93 TSHR (0.37) TSHRADORA2BADORA2AITGB3ITGA2B
SCHEMBL4186015 0.93 CHRNB2 (0.36) CHRNB2CHRNB4CHRNA3CHRNA4TSHR
SCHEMBL4178538 0.91 TSHR (0.36) TSHRADORA2BADORA2AITGB3ITGA2B
SCHEMBL4179679 0.91 CHRNB2 (0.38) CHRNB2CHRNB4CHRNA3CHRNA4TSHR
SCHEMBL4169858 0.91 ADORA2A (0.37) CHRNB2CHRNB4CHRNA3CHRNA4TSHR
SCHEMBL4178904 0.91 CHRNB2 (0.38) CHRNB2CHRNB4CHRNA3CHRNA4ADORA2B
SCHEMBL4186030 0.90 ADORA2A (0.36) CHRNB2CHRNB4CHRNA3CHRNA4TSHR
SCHEMBL4312584 0.89 TSHR (0.42) TSHRADORA2BADORA2AADORA1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090068101-A9 A1 Adenosine Receptor Antagonists ENDACEA, INC. (US) 2009-03-12 US disclosed
US-20070274910-A1 e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility ENDACEA, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070274910-A1 e.g. 3-[2-(2-Aminophenyl)ethyl]-8-benzyl-7-(2-methylamino)ethyl-1-propylxanthine; A1-adenosine receptor antagonist; antiallergen, antiinflammatory agent; AIDS and immune deficiency disorders, asthma; good water solubility HRH3, HRH1, HRH2 CHRNB2 237/4885CHRNB4 394/4885CHRNA3 121/4885
US-20090068101-A9 A1 Adenosine Receptor Antagonists ADORA1, ADORA3, ADORA2A CHRNB2 293/4885CHRNB4 306/4885CHRNA3 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.